paraneoplastic encephalitis associated with anti-ma2 antibodies and mesothelioma-like poorly differentiated lung cancer
Clicks: 336
ID: 132305
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
73.9
/100
336 views
231 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #10 of 49 articles by views in primates; journal of primatology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
We report a case of paraneoplastic encephalitis associated with anti-Ma2 antibodies. Medical history and thorax computed tomog-
raphy findings suggested malignant mesothelioma. Pleural biopsy results were compatible with high-grade neoplastic infiltration. Alt-
hough the biopsy could not differentiate the type of neoplasm, mesothelioma was considered a strong possibility in this poorly dif-
ferentiated lung carcinoma. To the best of our knowledge this is the first case report of paraneoplastic encephalitis associated with
anti-Ma2 antibodies and mesothelioma
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (76 words).
Try re-searching for a better abstract.
| Reference Key |
bekircan2009trkparaneoplastic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Can Ebru Bekircan;Amber Eker;Öztürk Ateş;Kader Karlı Oğuz |
| Journal | primates; journal of primatology |
| Year | 2009 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.